RespireRx Pharmaceuticals Inc (RSPI)

[moosedogger]

"...complicating the picture in 2007 to some extent will be the non-Ampakine in-license activity."

This is one facet of COR's strategy that seems questionable.

It doesn't seem to make sense considering COR's need for substantial resources to develop its Ampakine franchise.

Promising late stage compounds are in high demand (they're not cheap) by many players who have far greater resources and experience than COR.

Some of the competitors specialize in this strategy, which makes me wonder how COR expects to be able to find a hidden gem and avoid a lemon.

I can't see how COR is qualified to be venturing into this high risk area, as they seem to lack both the financial and developmental resources.

I'm concerned that COR will find themselves "in over their head" if they insist on that course.

Since Ampakines have so many potential applications in unmet medical needs, I can't see how diluting their efforts is a wise move.

I would like to hear why they believe they can be successful via the in-licensing route.

What happened to going with what you know?